Literature DB >> 7669824

What treatments do patients with panic disorder and agoraphobia get?

B Bandelow1, K Sievert, M Röthemeyer, G Hajak, E Rüther.   

Abstract

In a retrospective study 100 patients with DSM-III-R/ICD-10 panic disorder and agoraphobia (PDA) were interviewed about the psychopharmacological, psychological and 'alternative' treatments they had received in the course of their illness. Patients gave global statements about how satisfied they were with the various treatments they had experienced. Many patients received treatments that have never been investigated under controlled conditions. The most common drug treatments, in descending order, were: 48% benzodiazepines, 42% tricyclic antidepressants, 32% herbal preparations, 29% neuroleptics, 7% selective serotonin reuptake inhibitors and 6% beta blockers. Of the drug prescriptions, 63% were according to international standards. Of the neuroleptics, two-thirds (63.3%) were prescribed by nonpsychiatric physicians, and only one-third by psychiatrists (33.3%). Tricyclic antidepressants were prescribed more often by psychiatrists (64.7%) than by non-psychiatrists (31.4%). Among psychological treatments, autogenic training (43% of the patients) and psychodynamic therapy (33%) were used far more frequently than behavioural/cognitive therapy (20%). These results confirm the underutilisation of available effective treatments for panic disorder (e.g. tricyclic antidepressants or behavioural therapy) and the overutilisation of treatments without proven efficacy (e.g. herbal preparations or autogenic training). Patients were most satisfied with treatments that have been proven effective in controlled studies. Among drug treatments, benzodiazepines, selective serotonin inhibitors and tricyclic antidepressants were favoured (mean on a 0-4 scale indicating effectiveness: 2.6, 2.6 and 2.4). Neuroleptics (1.4), beta-blockers (1.0) and herbal preparations (0.9) were not rated highly effective by the patients. Among psychological treatments, patients were more satisfied with behavioural/cognitive therapy (2.6) than with psychodynamic therapies (1.5).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669824     DOI: 10.1007/bf02193090

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  26 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  Use of medication and in vivo exposure in volunteers for panic disorder research.

Authors:  C B Taylor; R King; J Margraf; A Ehlers; M Telch; W T Roth; W S Agras
Journal:  Am J Psychiatry       Date:  1989-11       Impact factor: 18.112

Review 3.  Use of benzodiazepines in anxiety disorders.

Authors:  R I Shader; D J Greenblatt
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

4.  Use of medical services and treatment for panic disorder with agoraphobia and for social phobia.

Authors:  R P Swinson; B J Cox; C B Woszczyna
Journal:  CMAJ       Date:  1992-09-15       Impact factor: 8.262

5.  Panic and avoidance in agoraphobia. Application of path analysis to treatment studies.

Authors:  D F Klein; D C Ross; P Cohen
Journal:  Arch Gen Psychiatry       Date:  1987-04

6.  Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine.

Authors:  M Mavissakalian; L Michelson
Journal:  J Clin Psychiatry       Date:  1986-03       Impact factor: 4.384

7.  A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.

Authors:  C L Ravaris; M J Friedman; P J Hauri; G J McHugo
Journal:  J Clin Psychopharmacol       Date:  1991-12       Impact factor: 3.153

8.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Authors:  J C Ballenger; G D Burrows; R L DuPont; I M Lesser; R Noyes; J C Pecknold; A Rifkin; R P Swinson
Journal:  Arch Gen Psychiatry       Date:  1988-05

9.  Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework.

Authors:  I M Marks; S Gray; D Cohen; R Hill; D Mawson; E Ramm; R S Stern
Journal:  Arch Gen Psychiatry       Date:  1983-02

Review 10.  Validation criteria for panic disorder as a nosological entity.

Authors:  R Rosenberg; J O Ottosson; P Bech; M Mellergård; N K Rosenberg
Journal:  Acta Psychiatr Scand Suppl       Date:  1991
View more
  1 in total

Review 1.  Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: a systematic review.

Authors:  Norio Watanabe; Rachel Churchill; Toshi A Furukawa
Journal:  BMC Psychiatry       Date:  2007-05-14       Impact factor: 3.630

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.